| 2025-01-30 14-13-16 | Sciatica is reduced by an average of 86% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Intervertebral Disc (IVD) |
| 2025-01-30 14-12-07 | Sciatica is reduced by an average of 79% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Intervertebral Disc (IVD) |
| 2025-01-30 14-08-07 | Sciatica is not significantly reduced at 3 months after after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-15-27 | Back Pain in the Lumbar Spine is reduced by an average of 71% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-13-47 | Back Pain in the Lumbar Spine is reduced by an average of 69% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-11-56 | Back Pain in the Lumbar Spine is reduced by an average of 62% at 3 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-29 10-54-58 | Intervertebral Disc (IVD) hydration is increased by an average of 16% at 12 months after intradiscal injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) |
| 2025-01-29 10-52-14 | Intervertebral Disc (IVD) height is not changed at 12 months after intradiscal injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) |